Holders — by stockHoldings — by fund
Privium Fund Management B.V.
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001795097
$515.5M
disclosed book value
58
positions
15.5%
largest position share
Positions, as of 2026-09-30
top 58 of 58 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | TSLATESLA INC | 225,000 | $79.8M | 15.5% |
| 2 | SHOPSHOPIFY INC | 305,000 | $45.2M | 8.8% |
| 3 | AMDADVANCED MICRO DEVICES INC | 62,000 | $37.9M | 7.4% |
| 4 | SPCXSPACE EXPLORATION TECHN CORP | 250,000 | $37.7M | 7.3% |
| 5 | PLTRPALANTIR TECHNOLOGIES INC | 200,000 | $37.4M | 7.3% |
| 6 | AMZNAMAZON COM INC | 140,000 | $34.9M | 6.8% |
| 7 | CBRSCEREBRAS SYSTEMS INC | 111,000 | $19.7M | 3.8% |
| 8 | NVDANVIDIA CORPORATION | 81,000 | $18.5M | 3.6% |
| 9 | SPOTSPOTIFY TECHNOLOGY S A | 33,000 | $16.1M | 3.1% |
| 10 | IONSIONIS PHARMACEUTICALS INC | 349,003 | $15.6M | 3% |
| 11 | IRENIREN LIMITED | 370,150 | $15.1M | 2.9% |
| 12 | ARWRARROWHEAD PHARMACEUTICALS IN | 215,818 | $14.1M | 2.7% |
| 13 | LMNDLEMONADE INC | 270,259 | $12.2M | 2.4% |
| 14 | OPENOPENDOOR TECHNOLOGIES INC | 5.1M | $12.2M | 2.4% |
| 15 | BIIBBIOGEN INC | 48,400 | $10.9M | 2.1% |
| 16 | NBISNEBIUS GROUP N.V. | 40,000 | $9.4M | 1.8% |
| 17 | PRQRPROQR THRAPEUTICS N V | 5.5M | $9.1M | 1.8% |
| 18 | ARQTARCUTIS BIOTHERAPEUTICS INC | 333,193 | $8.8M | 1.7% |
| 19 | AXSMAXSOME THERAPEUTICS INC. | 42,944 | $7.9M | 1.5% |
| 20 | BBIOBRIDGEBIO PHARMA INC | 89,151 | $5.9M | 1.1% |
| 21 | QUREUNIQURE NV | 216,197 | $5.2M | 1% |
| 22 | ALNYALNYLAM PHARMACEUTICALS INC | 20,607 | $5.1M | 1% |
| 23 | DNLIDENALI THERAPEUTICS INC | 229,857 | $4.8M | 0.9% |
| 24 | BMRNBIOMARIN PHARMACEUTICAL INC | 75,000 | $4.5M | 0.9% |
| 25 | URGNUROGEN PHARMA LTD | 107,915 | $4.4M | 0.9% |
| 26 | NBIXNEUROCRINE BIOSCIENCES INC | 26,200 | $3.7M | 0.7% |
| 27 | RAREULTRAGENYX PHARMACEUTICAL IN | 233,037 | $3.5M | 0.7% |
| 28 | KRYSKRYSTAL BIOTECH INC | 9,970 | $3.3M | 0.6% |
| 29 | BNTXBIONTECH SE | 32,100 | $3.2M | 0.6% |
| 30 | SRPTSAREPTA THERAPEUTICS INC | 166,605 | $3.0M | 0.6% |
| 31 | ABEVAMBEV SA | 989,723 | $2.9M | 0.6% |
| 32 | CRSPCRISPR THERAPEUTICS AG | 48,974 | $2.7M | 0.5% |
| 33 | MGTXMEIRAGTX HLDGS PLC | 208,512 | $2.3M | 0.4% |
| 34 | BEAMBEAM THERAPEUTICS INC | 91,282 | $2.2M | 0.4% |
| 35 | ZTSZOETIS INC | 23,643 | $1.7M | 0.3% |
| 36 | BTGB2GOLD CORP | 265,505 | $1.4M | 0.3% |
| 37 | FDMT4D MOLECULAR THERAPEUTICS IN | 90,110 | $1.3M | 0.3% |
| 38 | TSHATAYSHA GENE THERAPIES INC | 232,900 | $1.1M | 0.2% |
| 39 | RNACCARTESIAN THERAPEUTICS INC | 155,000 | $1.1M | 0.2% |
| 40 | FATEFATE THERAPEUTICS INC | 414,311 | $981,917 | 0.2% |
| 41 | AUTLAUTOLUS THERAPEUTICS LTD | 469,490 | $910,811 | 0.2% |
| 42 | RIGTRANSOCEAN LTD | 155,699 | $815,863 | 0.2% |
| 43 | MOHMOLINA HEALTHCARE INC | 4,064 | $768,502 | 0.1% |
| 44 | LULULULULEMON ATHLETICA INC | 7,023 | $675,542 | 0.1% |
| 45 | RCKTROCKET PHARMACEUTICALS INC | 244,146 | $642,104 | 0.1% |
| 46 | NOVNOV INC | 34,050 | $637,757 | 0.1% |
| 47 | LXEOLEXEO THERAPEUTICS INC | 155,000 | $523,900 | 0.1% |
| 48 | SDSANDRIDGE ENERGY INC | 38,792 | $523,304 | 0.1% |
| 49 | NUNU HLDGS LTD | 38,168 | $483,207 | 0.1% |
| 50 | SASEABRIDGE GOLD INC | 14,172 | $401,634 | 0.1% |
| 51 | URNMSPROTT FDS TR | 8,178 | $388,128 | 0.1% |
| 52 | ENGNENGENE THERAPEUTICS INC | 170,000 | $340,000 | 0.1% |
| 53 | VYGRVOYAGER THERAPEUTICS INC | 120,000 | $321,600 | 0.1% |
| 54 | RRCRANGE RES CORP | 7,147 | $264,725 | 0.1% |
| 55 | EXEEXPAND ENERGY CORPORATION | 3,046 | $256,138 | 0% |
| 56 | EQTEQT CORP | 5,266 | $255,717 | 0% |
| 57 | PFEPFIZER INC | 7,406 | $211,219 | 0% |
| 58 | COPYRBB FUND TRUST | 13,250 | $202,990 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.